Nicotinic acetylcholine receptor ligands, a patent review (2006 – 2011)

Bibliography

• Changeux JP, Taly A. Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med 2008;14:93-102
   PubMed Web of Science ®Google Scholar
• Tsetlin V, Kuzmin D, Kasheverov I. Assembly of nicotinic and other Cys-loop receptors. J Neurochem 2011;116:734-41
   PubMed Web of Science ®Google Scholar
• Wu J, Lukas RJ. Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem Pharmacol 2011;82:800-7
   PubMed Web of Science ®Google Scholar
• Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102-14
   PubMed Web of Science ®Google Scholar
• Plazas PV, Katz E, Gomez-Casati ME, Stoichiometry of the alpha9alpha10 nicotinic cholinergic receptor. J Neurosci 2005;25:10905-12
   PubMed Web of Science ®Google Scholar
• Gotti C, Clementi F, Fornari A, Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009;78:703-11
   PubMed Web of Science ®Google Scholar
• Gu R, Zhong YQ, Wei DQ. Structural basis of agonist selectivity for different nAChR subtypes: insights from crystal structures, mutation experiments and molecular simulations. Curr Pharm Des 2011;17:1652-62
   PubMed Web of Science ®Google Scholar
• Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 2011;82:915-30
   PubMed Web of Science ®Google Scholar
• Yakel JL. Gating of nicotinic ACh receptors: latest insights into ligand binding and function. J Physiol 2010;588:597-602
   PubMed Web of Science ®Google Scholar
• Wilson G, Karlin A. Acetylcholine receptor channel structure in the resting, open, and desensitized states probed with the substituted-cysteine-accessibility method. Proc Natl Acad Sci USA 2001;98:1241-8
   PubMed Web of Science ®Google Scholar
• Gotti C, Riganti L, Vailati S, Clementi F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 2006;12:407-28
   PubMed Web of Science ®Google Scholar
• Anderson D, Malysz J, Grønlien JH, Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination. Biochem Pharmacol 2009;78:844-51
   PubMed Web of Science ®Google Scholar
• Marks MJ, Meinerz NM, Brown RWB, Collins AC. 86Rb+ Efflux Mediated by alpha4beta2*-nicotinic acetylcholine receptors with high and low sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization. Biochem Pharmacol 2010;80:1238-51
   PubMed Web of Science ®Google Scholar
• Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007;47:699-729
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M, Rimondini R, Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391:173-7
   PubMed Web of Science ®Google Scholar
• Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992;107:285-9
   PubMed Web of Science ®Google Scholar
• Grottick AJ, Trube G, Corrigall WA, Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 2000;294:1112-19
   PubMed Web of Science ®Google Scholar
• Salminen O, Murphy KL, McIntosh JM, Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004;65:1526-35
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Karila L, Reynaud M. Pharmacotherapy for smoking cessation: present and future. Curr Pharm Des 2011;17:1343-50
   PubMed Web of Science ®Google Scholar
• Tonstad S, Davies S, Flammer M, Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33:289-301
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 2002;53:641-55
   PubMedGoogle Scholar
• Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010;16:323-43
   PubMed Web of Science ®Google Scholar
• Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000;74:237-43
   PubMed Web of Science ®Google Scholar
• Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26:25-40
   PubMed Web of Science ®Google Scholar
• Freedman R, Leonard S. Genetic linkage to schizophrenia at chromosome 15q14. Am J Med Genet 2001;105:655-7
   PubMed Web of Science ®Google Scholar
• Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33
   PubMed Web of Science ®Google Scholar
• Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 2003;165:386-96
   PubMed Web of Science ®Google Scholar
• Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 2002;25:272-5
   PubMed Web of Science ®Google Scholar
• Koike K, Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005;76:67-72
   PubMed Web of Science ®Google Scholar
• Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010;31:580-6
   PubMed Web of Science ®Google Scholar
• Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007;52:1256-62
   PubMed Web of Science ®Google Scholar
• Lippiello PM, Beaver JS, Gatto GJ, TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008;14:266-77
   PubMed Web of Science ®Google Scholar
• Granon S, Changeux JP. Attention-deficit/hyperactivity disorder: a plausible mouse model? Acta Paediatr 2006;95:645-9
   PubMed Web of Science ®Google Scholar
• Decker MW, Meyer MD. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem Pharmacol 1999;58:917-23
   PubMed Web of Science ®Google Scholar
• Decker MW, Curzon P, Holladay MW, The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J Physiol Paris 1998;92:221-4
   PubMedGoogle Scholar
• Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009;9:195-205
   PubMed Web of Science ®Google Scholar
• Improgo MR, Tapper AR, Gardner PD. Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer. Biochem Pharmacol 2011;82:1015-21
   PubMed Web of Science ®Google Scholar
• Improgo MR, Scofield MD, Tapper AR, Gardner PD. From smoking to lung cancer: the CHRNA5/A3/B4 connection. Oncogene 2010;29:4874-84
   PubMed Web of Science ®Google Scholar
• Beers WH, Reich E. Structure and activity of acetylcholine. Nature 1970;228:917-22
   PubMed Web of Science ®Google Scholar
• Glennon RA, Dukat M. Central nicotinic receptor ligands and pharmacophores. Pharm Acta Helv 2000;74:103-14
   PubMedGoogle Scholar
• Xiu X, Puskar NL, Shanata JAP, Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature 2009;458:534-7
   PubMed Web of Science ®Google Scholar
• Blum AP, Lester HA, Dougherty DA. Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH. Proc Natl Acad Sci USA 2010;107:13206-11
   PubMed Web of Science ®Google Scholar
• Sine SM. The nicotinic receptor ligand binding domain. J Neurobiol 2002;53:431-46
   PubMedGoogle Scholar
• Faghih R., Gopalakrishnan M, Briggs CA. Allosteric modulators of the alpha7 nicotinic acetylcholine receptor. J Med Chem 2008;51:701-12
   PubMed Web of Science ®Google Scholar
• Gundisch D. Nicotinic acetylcholine receptor ligands as potential therapeutics, Expert Opin Ther Patents. 2005;15:1-19
   Google Scholar
• Les Laboratoires Servier, France. Novel polysubstituted 1,1-pyridinyl aminocyclopropanamine derivatives, method for preparing same and pharmaceutical compositions containing same. WO2007012761; 2007
   Google Scholar
• Les Laboratoires Servier, Feance. Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them. WO2007085750; 2007
   Google Scholar
• Lagostena L, Danober L, Challal S, Modulatory effects of S 38232, a non a-7 containing nicotine acetylcholine receptor agonist on network activity in the mouse hippocampus. Neuropharmacology 2010;58:806-15
   PubMed Web of Science ®Google Scholar
• Howe WM, Ji J, Parikh V, Enhancement of Attentional Performance by Selective Stimulation of a4b2* nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010;35:1391-401
   PubMed Web of Science ®Google Scholar
• Aventis Pharma S.A., Fr. Triazine derivatives, their preparation and therapeutic application thereof. WO2006111662; 2006
   Google Scholar
• Bethesda Pharmacology Associates, LLC, USA. Nicotinic desensitizers and methods of selecting, testing, and using them. WO2008011484; 2008
   Google Scholar
• Georgetown University, USA. Silent desensitizers of neuronal nachr and methods of use thereof. WO2009143507; 2009
   Google Scholar
• PsychoGenics, Inc., USA. Nicotinic acetylcholine receptor ligands and the uses thereof. US20100152450; 2010
   Google Scholar
• The Regents of the University of California, USA. Labeled alpha-4-beta-2 ligands and methods therefor. WO2006086068; 2006
   Google Scholar
• Kyoto University, Japan. Method for producing azetidinylmethoxypyridine derivative and use of azetidinylmethoxypyridine derivative. WO2011040574; 2011
   Google Scholar
• Abbott Laboratories, USA. Neuronal nicotinic receptor ligands and their use. WO2007084535; 2011
   Google Scholar
• Targacept, Inc., USA. Synthesis and novel salt forms of (R)-5-((E)-2-(pyrrolidin-3-ylvinyl)pyrimidine. WO2010065443; 2010
   Google Scholar
• Targacept, Inc., USA. Novel compounds. WO2010065447; 2010
   Google Scholar
• Targacept, Inc., USA. (R) -3- (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydr0pyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors. WO2010065449; 2010
   Google Scholar
• Solvay Pharmaceuticals B.V., Netherlands. Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. WO2008003736; 2008
   Google Scholar
• Glaxo Group. 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands. WO2007138033; 2007
   Google Scholar
• Glaxo Group. Oxadiazole derivatives and their use as nicotinic acetylcholine receptor modulators. WO2009071519; 2009
   Google Scholar
• Glaxo Group. 5-aryl-1,3,4-oxadiazole-2-amines as nicotinic acetylcholine receptor agonists. WO2009071576; 2009
   Google Scholar
• Glaxo Group. Oxadiazole derivatives and their use as nicotinic acetylcholine receptor modulators. WO2009071577; 2009
   Google Scholar
• Critical Therapeutics, Inc., USA. Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof. WO2007089626; 2007
   Google Scholar
• University of Florida Research Foundation, Inc., USA. Alpha 7 nicotinic receptor selective ligands. WO2006133303; 2006
   Google Scholar
• University of Kentucky Research Foundation, USA. Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors. US20090143424; 2009
   Google Scholar
• University of Kentucky Research Foundation, USA. Tris-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors. WO2007076112; 2007
   Google Scholar
• University of Kentucky Research Foundation, USA. Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors. WO2007094912; 2007
   Google Scholar
• University of Kentucky Research Foundation, USA. Bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic acetylcholine receptors. WO2007133614; 2007
   Google Scholar
• University of Kentucky Research Foundation, USA. Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors. WO2007149163; 2007
   Google Scholar
• University of Kentucky Research Foundation, USA. Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors. WO2007149392; 2007
   Google Scholar
• Papke RL, Dwoskin LP, Crooks PA, Extending the analysis of nicotinic receptor antagonists with the study of a6 nicotinic receptor subunit chimeras Neuropharmacology. 2008;54:1189-200
   Google Scholar
• Rahman S, Zhang Z, Papke RL, Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br J Pharmacol 2008;153:792-804
   PubMed Web of Science ®Google Scholar
• Universite Laval, Can. Nicotinic receptor agonists for the treatment of inflammatory diseases. US20080221085; 2008
   Google Scholar
• Universite Laval, Can. Nicotinic receptor agonists for the treatment of inflammatory diseases. WO2006005195; 2006
   Google Scholar
• Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof. WO2007146066; 2007
   Google Scholar
• Targacept, Inc., USA. Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands. WO2010096384; 2010
   Google Scholar
• Wyeth, John, and Brother Ltd., USA; Siena biotech S.p.A. modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof. WO2007098826; 2007
   Google Scholar
• Wyeth, John, and Brother Ltd., USA; Siena biotech S.p.A. nicotinic acetylcholine receptor modulators. WO2008087529; 2008
   Google Scholar
• Wyeth, John, and Brother Ltd., USA; Siena biotech S.p.A. compounds useful as alpha7 nicotinic acetylcholine receptor agonists. US20090181952; 2009
   Google Scholar
• Wyeth, John, and Brother Ltd., USA; Siena Biotech S.p.A. Compound forms and uses thereof. US20090181953; 2009
   Google Scholar
• Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereoff. WO2006008133; 2006
   Google Scholar
• Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof. WO2007082731; 2007
   Google Scholar
• Bristol-Myers Squibb Co., USA. Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands. WO2011056503; 2011
   Google Scholar
• Universiteit Gent, Belg. Substituted 7-Azabicyclo[2.2.1]heptyl derivatives useful formaking pharmaceutical compositions. CA2638573; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicyclic aryl derivatives and their medical use. WO2006087305; 2006
   Google Scholar
• Targacept, Inc., USA. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands. WO2011071758; 2011
   Google Scholar
• Abbott Laboratories, USA. Biaryl substituted diazabicycloalkane derivatives. WO2009067586; 2009
   Google Scholar
• Bristol-Myers Squibb Co., USA. Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands. WO2011056573; 2011
   Google Scholar
• Sanofi Aventis, Fr. Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique. FR2889701; 2007
   Google Scholar
• Sanofi Aventis, Fr. Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics. WO2007020343; 2007
   Google Scholar
• Abbott Laboratories, USA. Fused bicycloheterocycle substituted azabicyclic alkane derivatives. WO2007137030; 2007
   Google Scholar
• Abbott Laboratories, USA. Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators. WO2009067579; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators. WO2009112462; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators. WO2010130768; 2010
   Google Scholar
• Pfizer, Inc., USA. Bicyclic diamines as nicotinic receptor agonists. WO2009081246; 2009
   Google Scholar
• Targacept, Inc., USA. Amides of diazabicyclooctanes and uses thereof. WO2010028033; 2010
   Google Scholar
• Targacept, Inc., USA. Heterocyclic-carbonyl-diazabicycloalkanes as modulators of the neuronal nicotinic acetylcholine alpha 4 beta 2, subtype receptor for the treatment of cns related disorders. WO2008112734; 2008
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicyclic aryl derivatives and their medical use. WO2006045716; 2006
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicyclic aryl derivatives and their medical use. WO2006087306; 2006
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicyclic aryl derivatives as cholinergy ligands. WO2006058879; 2006
   Google Scholar
• AstraZeneca AB, Swed. Nicotinic acetycholine receptor ligands. WO2006065217; 2006
   Google Scholar
• AstraZeneca AB, Swed. Nicotinic acetylcholine receptor ligands 101. WO2007133155; 2007
   Google Scholar
• AstraZeneca AB, Swed. Nicotinic acetylcholine receptor ligands 101. US20110136804; 2011
   Google Scholar
• AstraZeneca AB, Swed. Use of a nicotinic receptor agonist. WO2009066107; 2009
   Google Scholar
• Bristol-Myers Squibb Co., USA. Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands. US20090270405; 2009
   Google Scholar
• Universita Degli Studi di Milano, Italy; Consiglo Nazionale delle Ricerche. Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom. WO2008000469; 2008
   Google Scholar
• Abbott Laboratories. Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions. US20060211686; 2006
   Google Scholar
• Abbott Laboratories, USA. WO2006065233; 2006
   Google Scholar
• Abbott Laboratories, USA. Fused bicycloheterocycle substituted quinuclidine derivatives. US20070060588; 2007
   Google Scholar
• Abbott Laboratories, USA. Fused bicycloheterocycle substituted quinuclidine derivatives. US20080064703; 2008
   Google Scholar
• Neurosearch A/S, Den. Novel azabicyclic aryl derivatives and their medical use. WO2006040352; 2006
   Google Scholar
• Neurosearch A/S, Den. Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands. WO2006040352; 2006
   Google Scholar
• Neurosearch A/S, Den. Den. Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators. WO2009150141; 2009
   Google Scholar
• Targacept, Inc., USA. heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof. WO2007024814; 2007
   Google Scholar
• Targacept, Inc., USA. (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof. WO2009018505; 2009
   Google Scholar
• Targacept, Inc., USA. Preparation and therapeutic applications of (2S,3R)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide. WO2010085724; 2010
   Google Scholar
• Targacept, Inc., USA. Treatment with alpha a7-selective ligands. WO2010056622; 2010
   Google Scholar
• Memory Pharmaceuticals Corp., USA. Nicotinic alpha-7 receptor ligands and preparation and uses thereof. WO2006069097; 2006
   Google Scholar
• Memory Pharmaceuticals Corp., USA. Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof. WO2007038367; 2007
   Google Scholar
• Comentis, Inc., USA. 4-Substituted quinuclidine derivatives, methods of production, and pharmaceutical uses thereof. US20090088418; 2009
   Google Scholar
• Novartis AG, Switz.; Novartis Pharma GmbH. 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases. WO2006005608; 2006
   Google Scholar
• Targacept, Inc., USA. Sub-type selective azabicycloalkane derivatives. WO2008121686; 2008
   Google Scholar
• Targacept, Inc., USA. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes. WO2008057938; 2008
   Google Scholar
• Pfizer Products, Inc., USA. 1, 2, 3, 3A, 8, 8A-hexahydro-2, 7a-diada-cyclopenta [a] inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders. WO2006061711; 2006
   Google Scholar
• Abbott Laboratories, USA. Selective ligands for the neuronal nicotinic receptors and uses thereof. WO2009137308; 2009
   Google Scholar
• Novartis A.-G., Switz.; Novartis Pharma GmbH. (1-Aza-bicyclo[3.3.1] non-4-yl)-[5-(ih-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders. WO2007068475; 2007
   Google Scholar
• Novartis A.-G., Switz.; Novartis Pharma G.m.b.H. Novartis pharma gmbh. [(1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. WO2007068476; 2007
   Google Scholar
• Eli Lilly and Co., USA. Azabicycloalkane derivatives useful as nicotinic acetylcholine receptor agonists. WO2006096358; 2006
   Google Scholar
• SRI International, USA. Nicotinic acetylcholine receptor modulators. WO2009058120; 2009
   Google Scholar
• SRI International, USA. Nicotinic Acetylcholine Receptor Modulators. US20090118326; 2009
   Google Scholar
• Targacept, Inc., USA. The use of N-aryl diazaspiracyclic compounds in the treatment of addiction. WO2006023630; 2006
   Google Scholar
• Targacept, Inc., USA. Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes. WO2008057938; 2008
   Google Scholar
• Targacept, Inc., USA. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes. WO2009111550; 2009
   Google Scholar
• Targacept, Inc., USA. Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands. WO2010002971; 2010
   Google Scholar
• Georgetown University, USA. 10-Substituted cytisine derivatives and methods of use thereof. WO2007115092; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicyclic aryl derivatives and their medical use. WO2007065892; 2007
   Google Scholar
• Neurosearch A/S, Den. 3-Heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists. WO2007090888; 2007
   Google Scholar
• Neurosearch A/S, Den. Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods. WO2009150139; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel diazabicycloalkane derivatives and their medical use. WO2007093600; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use. WO2007135120; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use. WO2007135122; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use. WO2007138037; 2007
   Google Scholar
• Neurosearch A/S, Den. Ovel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use. WO2007138039; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use. WO2007138038; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use. WO2007138040; 2007
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use. WO2007138041; 2007
   Google Scholar
• Neurosearch A/S, Den. 1,4-diaza-bicyclo(3.2.2)Nonyl Pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands. WO2009024515; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands. WO2009024516; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands. WO2009024517; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use. WO2009062987; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use. WO2009062988; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use. WO2009062989; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors. WO2009112460; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel oxadiazolyl-diazabicyclononane derivatives and their medical use. WO2009150138; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel N-oxides of furanyl-oxadiazolyl-diazabicyclononane derivatives and their medical use. WO2010086280; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their medical use. WO2010086279; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use. WO2010084185; 2010
   Google Scholar
• Neurosearch A/S, Den. N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use. WO2010084184; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel diaza-bicyclononyl-phenyl derivatives and their medical use. WO2010063784; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel oxadiazolyl-diazabicyclononane derivatives and their medical use. WO2010043539; 2010
   Google Scholar
• Neurosearch A/S, Den. 1,4-diaza-bicyclo [3.2.2] nonyl pyridine derivatives as nicotinic and monoamine receptor modulators. WO2010026177; 2010
   Google Scholar
• Neurosearch A/S, Den. 1,4-diaza- bicyclo [3.2.2]nonyl pyrimidine derivatives as nicotinic and monoamine receptor modulators. WO2010026176; 2010
   Google Scholar
• Neurosearch A/S, Den. Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators. WO2011073296; 2011
   Google Scholar
• Neurosearch A/S, Den. Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods. WO2011058002; 2011
   Google Scholar
• Pfizer Products, Inc., USA. Azabenzoxazoles for the treatment of cns disorders. WO2006051394; 2006
   Google Scholar
• Pfizer Products, Inc., USA. Azabenzoxazoles for the treatment of cns disorders. WO2006051407; 2006
   Google Scholar
• Pfizer Products, Inc., USA. Azabenoxazoles for the treatment of cns disorders. WO2006051413; 2006
   Google Scholar
• Pfizer Products, Inc., USA. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane. WO2007017750; 2007
   Google Scholar
• Memory Pharmaceuticals Corp., USA. 1 H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof. WO2007056582; 2007
   Google Scholar
• Memory Pharmaceuticals Corp., USA. (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease. WO2009055437; 2009
   Google Scholar
• Targacept, Inc., USA. Amides of diazabicyclononanes and uses thereof. WO2010028011; 2011
   Google Scholar
• Targacept, Inc., USA. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity. WO2006034089; 2006
   Google Scholar
• Neurosearch A/S, Den. Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use. WO2007135121; 2007
   Google Scholar
• Abbott Laboratories, USA. Amino-aza-adamantane derivatives and methods of use. US20070072892; 2007
   Google Scholar
• Abbott Laboratories, USA. Spirocyclic azaadamantane derivatives and methods of use. US20080153860; 2008
   Google Scholar
• Abbott Laboratories, USA. Spirocyclic azaadamantane derivatives and methods of use. WO2008079570; 2008
   Google Scholar
• Abbott Laboratories, USA. Azaadamantane derivatives and methods of use. WO2008058096; 2008
   Google Scholar
• Abbott Laboratories, USA. Azaadamantane ester and carbamate derivatives and methods of use thereof. WO2008118742; 2008
   Google Scholar
• Abbott Laboratories, USA. Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof. WO2008118743; 2008
   Google Scholar
• Abbott Laboratories, USA. 4-substituted azaadamantane derivatives and methods of use thereof. WO2008118745; 2008
   Google Scholar
• Abbott Laboratories, USA. Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (NNRS). WO2008118747; 2008
   Google Scholar
• Abbott Laboratories, USA. Diazahomoadamantane derivatives and methods of use thereof. WO2010145208; 2010
   Google Scholar
• Abbott Laboratories, USA. 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof. WO2010151815; 2010
   Google Scholar
• Abbott Laboratories, USA. Aza-cylic indole-2-carboxamides and methods of use thereof. WO2009158375; 2009
   Google Scholar
• Abbott Laboratories, USA. Pharmaceutical compositions and their methods of use. US20080167286; 2008
   Google Scholar
• Abbott Laboratories, USA. Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof. US20080269236; 2008
   Google Scholar
• Abbott Laboratories, USA. Pharmaceutical compositions and their methods of use. WO2008073942; 2008
   Google Scholar
• Abbott Laboratories, USA. Heterocyclic compounds and their methods of use. US20080255203; 2008
   Google Scholar
• Abbott Laboratories, USA. Heterocyclic compounds and their methods of use. WO2008127464; 2008
   Google Scholar
• Abbott Laboratories, USA. Novel 1,2,4 oxadiazole compounds and methods of use thereof. WO2009148452; 2009
   Google Scholar
• Abbott Laboratories, USA. Pharmaceutical compositions for the treatment of pain. WO2010138600; 2010
   Google Scholar
• Abbott Laboratories, USA. Bis (hetero) aryl substituted isoxazoles for use as neuronal nicotinic receptor modulators. WO2009149135; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel oxadiazole derivatives and their medical use. WO2006114400; 2006
   Google Scholar
• Neurosearch A/S, Den. Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators. WO2008049864; 2008
   Google Scholar
• Neurosearch A/S, Den. Pyridinyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators. WO2011073299; 2011
   Google Scholar
• Neurosearch A/S, Den. Triazole derivatives and their use as nicotinic acetylcholine receptor modulators. WO2010026134; 2010
   Google Scholar
• Neurosearch A/S, Den. 2, 5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators. WO2010106106; 2010
   Google Scholar
• Neurosearch A/S, Den. Tetrazole derivatives as nicotinic acetylcholine receptor modulators. WO2011073298; 2011
   Google Scholar
• Neurosearch A/S, Den. Tetrazole derivatives as nicotinic acetylcholine receptor moudlators. WO2011073297; 2011
   Google Scholar
• Abbott Laboratories, USA. Thiazoline and oxazoline derivatives and their methods of use. WO2008002956; 2008
   Google Scholar
• Abbott Laboratories, USA. WO2009086163. Thiazolylidine urea and amide derivatives and methods of use thereof. 2009
   Google Scholar
• Abbott Laboratories, USA. Pyrrole derivatives and their methods of use. WO2008002974; 2008
   Google Scholar
• Abbott Laboratories, USA. Amide derivatives as positive allosteric modulators and methods of use thereof. WO2009100294; 2009
   Google Scholar
• AstraZeneca AB, Swed. Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors. WO2006068591; 2006
   Google Scholar
• AstraZeneca AB, Swed. Aryl sulphonamide modulators. WO2006071184; 2006
   Google Scholar
• AstraZeneca AB, Swed. Alpha 7 modulators. WO2007001225; 2007
   Google Scholar
• Glaxo Group Ltd, UK. Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71. WO2009127678; 2009
   Google Scholar
• Glaxo Group Ltd, UK. Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7. WO2009127679; 2009
   Google Scholar
• Glaxo Group Ltd, UK. Indole derivative modulators of the alpha 7 nachr. WO2010119078; 2010
   Google Scholar
• Glaxo Group Ltd, UK. Indole and azaindole modulators of the alpha 7 nachr. WO2011045353; 2011
   Google Scholar
• Janssen Pharmaceutica. 2-aniline-4-aryl substituted thiazole derivatives. WO2007031440; 2007
   Google Scholar
• Janssen Pharmaceutica. Trisubstituted 1,2,4-triazoles. WO2007118903; 2007
   Google Scholar
• Janssen Pharmaceutica. 1,3,5-trisubstituted triazole derivative. WO2009050185; 2009
   Google Scholar
• Janssen Pharmaceutica. Trisubstituted 1,2,4-triazoles. WO2009050186; 2009
   Google Scholar
• Janssen Pharmaceutica. Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators. WO2009115547; 2009
   Google Scholar
• Janssen Pharmaceutica. Trisubstituted pyrazoles as acetylcholine receptor modulators. WO2009135944; 2009
   Google Scholar
• Janssen Pharmaceutica. Morpholinothiazoles as alpha 7 positive allosteric modulators. WO2011064288; 2011
   Google Scholar
• Neurosearch A/S, Den. Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors. WO2009019278; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors. WO2009112459; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors. WO2010015583; 2010
   Google Scholar
• Neurosearch A/S, Den. N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors. WO2009065850; 2009
   Google Scholar
• Neurosearch A/S, Den. N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors. WO2009065854; 2009
   Google Scholar
• Neurosearch A/S, Den. Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors. WO2009112461; 2009
   Google Scholar
• Neurosearch A/S, Den. 6-Phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors. WO2010040826; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel diphenyl purine derivatives useful as modulators of nicotinic acetylcholine receptors. WO2010040806; 2010
   Google Scholar
• Neurosearch A/S, Den. Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors. WO2010020672; 2010
   Google Scholar
• F. Hoffmann-La Roche AG, Switz. Tetrazole-substituted aryl amide derivatives and uses thereof. WO2009043780; 2009
   Google Scholar
• F. Hoffmann-La Roche AG, Switz. Cyclopropyl aryl amide derivatives and uses thereof. WO2009043784; 2009
   Google Scholar
• The Regents of the University of California, USA. Substituted enaminones as nicotinic acetylcholine receptor modulators. WO2006138510; 2006
   Google Scholar
• University of California, USA. Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors. WO2010104843; 2010
   Google Scholar
• Anvyl, LLC, USA. Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof. WO2010083444; 2010
   Google Scholar